Phase I Dose-Finding Study of Eribulin and Capecitabine for Metastatic Breast Cancer: JBCRG-18 Cape Study

Breast Cancer - Japan
doi 10.1007/s12282-017-0798-4
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Phase II Study of Carboplatin, Vinorelbine and Capecitabine in Patients With Metastatic Breast Cancer

The Internet Journal of Oncology
2007English

A Phase 1b/2, Open-Label, Dose-Escalation, and Dose-Confirmation Study of Eribulin Mesilate in Combination With Capecitabine

British Journal of Cancer
Cancer ResearchOncology
2019English

A Phase II Study of Oxaliplatin, Dose-Intense Capecitabine, and High-Dose Bevacizumab in the Treatment of Metastatic Colorectal Cancer

Clinical Colorectal Cancer
OncologyGastroenterology
2011English

Phase I Study of Intermittent High Dose Lapatinib Alternating With Capecitabine for HER2-positive Breast Cancer Patients With Central Nervous System Metastases

Clinical Cancer Research
Cancer ResearchOncology
2019English

Phase II, Multicenter, Single-Arm, Feasibility Study of Eribulin Combined With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive, Early-Stage Breast Cancer

Clinical Breast Cancer
Cancer ResearchOncology
2016English

Metastatic Breast Cancer: Focus on Capecitabine

Clinical Medicine Reviews in Oncology
2010English

Phase II Study of Pembrolizumab and Capecitabine for Triple Negative and Hormone Receptor-Positive, HER2−negative Endocrine-Refractory Metastatic Breast Cancer

Journal for ImmunoTherapy of Cancer
OncologyMolecular MedicinePharmacologyCancer ResearchAllergyImmunology
2020English

Phase I Study of Panobinostat (LBH589) and Letrozole in Postmenopausal Metastatic Breast Cancer Patients

Clinical Breast Cancer
Cancer ResearchOncology
2016English

Eribulin in Pretreated Metastatic Breast Cancer Patients: Results of the TROTTER Trial—a Multicenter Retrospective Study of Eribulin in Real Life

SpringerPlus
Multidisciplinary
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy